Business Wire

Pepper Advantage Sees Signs of Rising Default Risk in Spanish Residential Mortgage Market

20.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Pepper Advantage, a global credit intelligence company, has released data which points to potential future increases in credit impairments in the Spanish residential mortgage market. Using data derived from its credit intelligence platform, Pepper Advantage is able to track payment failures – or Direct Debit Rejections (DDRs) – in real time, building a picture of borrower stress across its portfolios of residential mortgages.

DDRs occur when a customer’s standing order fails to complete, usually indicating that the customer has insufficient funds in their account to meet the mortgage repayment request. Pepper Advantage considers DDRs to be a reliable leading indicator of borrower stress and potential future default risk, even if the borrower subsequently satisfies the loan repayment requirement another way.

In the six months to December 2022, Pepper Advantage saw a biannual 7.85% increase in DDR rates across its mortgage portfolios, a trend that correlates with increases in Euribor. Euribor is the rate at which European banks lend to one another and typically correlates to the cost of credit in the Spanish mortgage market for variable interest rate mortgages. Pepper Advantage’s predictive model suggests there was an average monthly DDR increase of 0.6% for every ECB interest rate rise of 50bps in the second half of 2022.

The national biannual increase in DDRs of 7.85% represents variations across the country, with higher levels of relative stress in areas such as Andalucía, Extremadura, Asturias, Murcia and Castilla La Mancha. This regional analysis takes into account respective employment and GDP rates to create different predictive ratios for borrower stress as rates rise.

Approximately 75% of all mortgages in Spain are on variable interest rates, referenced to Euribor, which are updated every six or 12 months. This implies a significant lag between initial indicators of borrower stress – identified by Pepper Advantage – and the potential future realisation of the loan impairment.

Pepper Advantage has the ability to identify potential problem loans early, which gives it a significant edge in designing and implementing borrower strategies that can avoid dramatic increases in defaults. As a result, default levels across Pepper Advantage’s mortgage portfolios have remained low by historical levels, despite rising indications of borrower difficulties.

Commenting on the data, Juan Arsuaga, Head of Client Solutions, Pepper Advantage Spain said:

"We are seeing Spanish borrowers dip into savings and turn to other forms of unsecured credit to cover the instalments of their variable interest rate mortgages, as last year’s rate rises begin to feed through. It’s therefore more important than ever that financial investors, lenders and credit managers are able to identify potentially problematic borrowers at an early stage and put in place management measures to help them avoid defaulting on their loans.”

Ends

About Pepper Advantage

Pepper Advantage is a global credit intelligence company that offers a range of advisory and credit management services across Asia, Europe, and the United Kingdom. The company operates in multiple asset classes including residential and commercial mortgages, real estate, SME loans, asset financing and leasing, auto and consumer loans, credit cards, retail finance and BNPL, in addition to offering a number of outsourced operational support services to both financial and non-financial clients. It helps investors, financial institutions, fintechs, and banks manage their credit portfolios, with a particular focus on clients whose customers are underserved by traditional mainstream lenders. Follow on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Eterna Partners
PepperAdvantage@eternapartners.com
+44 07503 408 251

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye